secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001140361-26-002070
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise
--------------------------------------------------------------------------------

- Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.
- Proceeds to fund global pivotal PARADIGM trial and global commercialization of DurAVR THV (transcatheter heart valve).
- PARADIGM trial is a randomized controlled trial of ~1000 patients comparing DurAVR THV to commercially available TAVRs; enrollment started Q4 2025.
- Medtronic and Anteris may expand collaboration into other strategic areas; Medtronic joins Anteris' stockholder community.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126002070/0001140361-26-002070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126002070/ny20062007x8_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-002070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer